Kyntra Bio

Kyntra Bio EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Kyntra Bio (KYNB) as of Oct 24, 2026 is -5.55. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -0.38 — a change of 1,354.44% (lower).

EV/FCF

-5.55

YoY

1,354.44%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Kyntra Bio is 2025 -5.55 . EV/FCF (Enterprise Value to Free Cash Flow) of Kyntra Bio was 2024 -0.38 . It decreases by 1,354.44% lower compared to the previous year.

The Kyntra Bio EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
5.87 USD
Jan 1, 2019
5.35 USD
Jan 1, 2020
-7.95 USD
Jan 1, 2021
2.45 USD
Jan 1, 2022
1.64 USD
Jan 1, 2023
0.11 USD
Jan 1, 2024
-0.38 USD
Jan 1, 2025
-5.55 USD
The Kyntra Bio EV/FCF history
YEAREV/FCFYoY
-5.55+1,354.44%
-0.38-446.20%
0.11-93.26%
1.64-33.23%
2.45-130.82%
-7.95-248.57%
5.35-8.90%
5.87-27.55%
8.10-137.75%
-21.46-916.86%
2.63-171.60%
-3.67—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kyntra Bio Stock analysis

What does Kyntra Bio do? Kyntra Bio Inc is a biopharmaceutical company based in San Francisco, United States, operating within the health care sector. Listed on November 14, 2014, the firm engages in the discovery, development, and commercialization of novel therapeutics. It leverages expertise in hypoxia-inducible factor and connective tissue growth factor biology to create innovative medicines. The company is developing roxadustat for anemia associated with chronic kidney disease, myelodysplastic syndromes, and chemotherapy-induced anemia. Additionally, it is researching pamrevlumab for conditions such as idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy. The organization currently employs 34 people in its operations. Kyntra Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kyntra Bio stock

EV/FCF (Enterprise Value to Free Cash Flow) of Kyntra Bio is -5.55 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Kyntra Bio changed from -0.38 to -5.55, representing a 1,354.44% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Kyntra Bio since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Kyntra Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Kyntra Bio

All Key Metrics — Kyntra Bio